Seminars in Oncology
Volume 33, Issue 5 , Pages 583-587, October 2006

Interleukin-2 Therapy of Metastatic Renal Cell Carcinoma—Predictors of Response

  • David F. McDermott

      Affiliations

    • Corresponding Author InformationAddress correspondence to David F. McDermott, MD, Chair, Clinical Research Sub-Committee, DF/HCC Renal Cancer Program, Kirstein Room 153, Beth Israel Deaconess Medical Center, 330 Brookline Ave, Boston, MA 02215, USA.
    • D.F.M. is a Consultant for Genentech, Bayer, and Onyx, and is on the Speaker’s Bureau for Chiron.
    • ,
  • Michael B. Atkins

      Affiliations

    • M.B.A is a Consultant for Chiron, Schering, Bayer, Onyx, Pfizer, Wyeth, Wilex, Novartis, Genentech, and NovoNordisk, and is on the Speaker’s Bureau for Chiron, Bayer, and Onyx.

Beth Israel Deaconess Medical Center and the Dana-Farber/Harvard Cancer Center Renal Cancer Program, Boston, MA.

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.

 Supported in part by the DF/HCC Renal Cancer SPORE: P50 CA101942-01.

PII: S0093-7754(06)00270-3

doi:10.1053/j.seminoncol.2006.06.004

Seminars in Oncology
Volume 33, Issue 5 , Pages 583-587, October 2006

Article Tools